Dyne Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share. The offering is expected to close on or about July 23, 2026, and is expected to yield net proceeds of approximately $352.1 million. Dyne Therapeutics is a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
